{"groups":[{"description":"Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.\n\nPhase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.\n\nPhase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.\n\nSelinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.\n\nPhase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.\n\nSorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.\n\nPhase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.","id":"FG000","title":"Phase I Group 1 Selinexor + Sorafenib"},{"description":"Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.\n\nPhase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.\n\nPhase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle. Phase I Group 2 received Selinexor 80 mg by mouth twice weekly for a 28 day cycle.","id":"FG001","title":"Phase I Group 2 Selinexor + Sorafenib"},{"description":"Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.\n\nPhase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.\n\nPhase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.\n\nSelinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.\n\nPhase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.\n\nSorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.\n\nPhase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.","id":"FG002","title":"Cohort 1 (FLT3-ITD Inhibitor Failure Cohort)"},{"description":"Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.\n\nPhase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.\n\nPhase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.\n\nSelinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.\n\nPhase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.\n\nSorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.\n\nPhase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.","id":"FG003","title":"Cohort 2 (FLT3-ITD Inhibitor Naive Cohort)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"3"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"3"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Recruitment Period: December 2015 to July 2018"}